Whole Chromosome Alterations Predict Survival in High-risk Neuroblastoma Without MYCN Amplification

Overview

Journal Clin Cancer Res

Specialty Oncology

Date 2008 Sep 4

PMID 18765546

Citations 12

Authors

Sven Bilke

Qing-Rong Chen

Jun S Wei

Javed Khan

Affiliations

Soon will be listed here.

Abstract

Purpose: Patients with stage IV neuroblastoma over the age of 500 days without MYCN amplification have a survival rate of <30% and there are currently no reliable means of predicting which of these patients will survive or succumb to the disease. The goal of this study is to develop a DNA copy number-based prognostic profile for these patients.

Experimental Design: We have used comparative genomic hybridization to identify genome copy number changes that can predict outcome in patients with stage IV neuroblastoma without MYCN amplification.

Results: A strong correlation of patient survival with the presence of whole chromosome changes (WCC >or=2) was observed, even in the group of patients older than 500 days at time of diagnosis. This novel prognostic marker showed a significant dependence on the date of diagnosis; patients with WCC >or=2 diagnosed after 1998 had a significantly higher probability of survival compared with those diagnosed earlier. At the same time, no such time dependence was found among the samples with WCC <2, suggesting that medical progress patients in recent years has particularly benefited those patients with a stage IV non-MYCN-amplified disease if WCC >or=2 were present.

Conclusions: In this pilot study, we present a novel prognostic marker for survival of high-risk neuroblastoma patients over the age of 500 days without MYCN amplification and diagnosed after 1998. Further validation study is required to establish this risk stratification for these patients.

Citing Articles

Application of the FISH method and high-density SNP arrays to assess genetic changes in neuroblastoma-research by one institute.

Winnicka D, Skowera P, Stelmach M, Styka B, Lejman M Acta Biochim Pol. 2024; 71:12821.

PMID: 39049899 PMC: 11267511. DOI: 10.3389/abp.2024.12821.

Multi-omics integration reveals a six-malignant cell maker gene signature for predicting prognosis in high-risk neuroblastoma.

Yan Z, Liu Q, Cao Z, Wang J, Zhang H, Liu J Front Neuroinform. 2022; 16:1034793.

PMID: 36439943 PMC: 9687102. DOI: 10.3389/fninf.2022.1034793.

New insights in pediatrics in 2021: choices in allergy and immunology, critical care, endocrinology, gastroenterology, genetics, haematology, infectious diseases, neonatology, neurology, nutrition, palliative care, respiratory tract illnesses and....

Caffarelli C, Santamaria F, Piro E, Basilicata S, Delle Cave V, Cipullo M Ital J Pediatr. 2022; 48(1):189.

PMID: 36435791 PMC: 9701393. DOI: 10.1186/s13052-022-01374-8.

Bioinformatics analysis of recurrent deletion regions in neuroblastoma.

Caglar H Med Oncol. 2022; 39(3):31.

PMID: 35059899 DOI: 10.1007/s12032-021-01639-y.

Spatial and temporal intratumour heterogeneity has potential consequences for single biopsy-based neuroblastoma treatment decisions.

Schmelz K, Toedling J, Huska M, Cwikla M, Kruetzfeldt L, Proba J Nat Commun. 2021; 12(1):6804.

PMID: 34815394 PMC: 8611017. DOI: 10.1038/s41467-021-26870-z.

References

Chen Y, Stallings R . Differential patterns of microRNA expression in neuroblastoma are correlated with prognosis, differentiation, and apoptosis. Cancer Res. 2007; 67(3):976-83. DOI: 10.1158/0008-5472.CAN-06-3667. View

Mosse Y, Diskin S, Wasserman N, Rinaldi K, Attiyeh E, Cole K . Neuroblastomas have distinct genomic DNA profiles that predict clinical phenotype and regional gene expression. Genes Chromosomes Cancer. 2007; 46(10):936-49. DOI: 10.1002/gcc.20477. View

Wei J, Greer B, Westermann F, Steinberg S, Son C, Chen Q . Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004; 64(19):6883-91. PMC: 1298184. DOI: 10.1158/0008-5472.CAN-04-0695. View

Chen Q, Bilke S, Wei J, Whiteford C, Cenacchi N, Krasnoselsky A . cDNA array-CGH profiling identifies genomic alterations specific to stage and MYCN-amplification in neuroblastoma. BMC Genomics. 2004; 5:70. PMC: 520814. DOI: 10.1186/1471-2164-5-70. View

Bilke S, Chen Q, Westerman F, Schwab M, Catchpoole D, Khan J . Inferring a tumor progression model for neuroblastoma from genomic data. J Clin Oncol. 2005; 23(29):7322-31. DOI: 10.1200/JCO.2005.03.2821. View

Bilke S, Chen Q, Whiteford C, Khan J . Detection of low level genomic alterations by comparative genomic hybridization based on cDNA micro-arrays. Bioinformatics. 2004; 21(7):1138-45. DOI: 10.1093/bioinformatics/bti133. View

London W, Castleberry R, Matthay K, Look A, Seeger R, Shimada H . Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol. 2005; 23(27):6459-65. DOI: 10.1200/JCO.2005.05.571. View

Vandesompele J, Speleman F, van Roy N, Laureys G, Brinskchmidt C, Christiansen H . Multicentre analysis of patterns of DNA gains and losses in 204 neuroblastoma tumors: how many genetic subgroups are there?. Med Pediatr Oncol. 2001; 36(1):5-10. DOI: 10.1002/1096-911X(20010101)36:1<5::AID-MPO1003>3.0.CO;2-E. View

Ohira M, Oba S, Nakamura Y, Isogai E, Kaneko S, Nakagawa A . Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas. Cancer Cell. 2005; 7(4):337-50. DOI: 10.1016/j.ccr.2005.03.019. View

10.

Nowell P . The clonal evolution of tumor cell populations. Science. 1976; 194(4260):23-8. DOI: 10.1126/science.959840. View

11.

Attiyeh E, London W, Mosse Y, Wang Q, Winter C, Khazi D . Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005; 353(21):2243-53. DOI: 10.1056/NEJMoa052399. View

12.

Matthay K, Villablanca J, Seeger R, Stram D, Harris R, Ramsay N . Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group. N Engl J Med. 1999; 341(16):1165-73. DOI: 10.1056/NEJM199910143411601. View

13.

Selzer R, Richmond T, Pofahl N, Green R, Eis P, Nair P . Analysis of chromosome breakpoints in neuroblastoma at sub-kilobase resolution using fine-tiling oligonucleotide array CGH. Genes Chromosomes Cancer. 2005; 44(3):305-19. DOI: 10.1002/gcc.20243. View

14.

Maris J . The biologic basis for neuroblastoma heterogeneity and risk stratification. Curr Opin Pediatr. 2005; 17(1):7-13. DOI: 10.1097/01.mop.0000150631.60571.89. View

15.

Asgharzadeh S, Pique-Regi R, Sposto R, Wang H, Yang Y, Shimada H . Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification. J Natl Cancer Inst. 2006; 98(17):1193-203. DOI: 10.1093/jnci/djj330. View

16.

Schramm A, Vandesompele J, Schulte J, Dreesmann S, Kaderali L, Brors B . Translating expression profiling into a clinically feasible test to predict neuroblastoma outcome. Clin Cancer Res. 2007; 13(5):1459-65. DOI: 10.1158/1078-0432.CCR-06-2032. View

17.

Bowman L, Castleberry R, Cantor A, Joshi V, Cohn S, SMITH E . Genetic staging of unresectable or metastatic neuroblastoma in infants: a Pediatric Oncology Group study. J Natl Cancer Inst. 1997; 89(5):373-80. DOI: 10.1093/jnci/89.5.373. View

18.

George R, London W, Cohn S, Maris J, Kretschmar C, Diller L . Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study. J Clin Oncol. 2005; 23(27):6466-73. DOI: 10.1200/JCO.2005.05.582. View

19.

Maris J, Hogarty M, Bagatell R, Cohn S . Neuroblastoma. Lancet. 2007; 369(9579):2106-20. DOI: 10.1016/S0140-6736(07)60983-0. View

20.

Oberthuer A, Berthold F, Warnat P, Hero B, Kahlert Y, Spitz R . Customized oligonucleotide microarray gene expression-based classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol. 2006; 24(31):5070-8. DOI: 10.1200/JCO.2006.06.1879. View